FTO-mediated m6A modification of circGDI2 promotes HCC proliferation and glycolysis via the IGF2BP2/PKM2 axis, suggesting circGDI2 as a potential therapeutic target for HCC. This evidence concerns the gene PKM and hepatocellular carcinoma.